Innovating from a cost-benefit analysis based on Palivizumabe 2019/2020 performance indicators in a Neonatal Unit in the city of Niterói, Rio de Janeiro.

Abstract

ABSTRACT
INNOVATION PROCESS IN THE HEALTH AREA HAS PROMOTED CHANGES IN
MANAGEMENT AND WITH A CONSEQUENTIAL IMPROVEMENT OF THE COST
BENEFIT OF PATIENT TREATMENT (CHRISTENSEN,2009). THE USE OF
INDICATORS THAT COME TO MEASURE MANAGEMENT PERFORMANCE
THROUGH BALANCED METRICS - BALANCED SCORECARD (KAPLAN, 1996) HAS
EVEN MORE CONTRIBUTED TO THIS MANAGEMENT WITH THE USE OF
INDICATORS AND CORRELATION BETWEEN THEM. THIS RESEARCH AIMS TO
PERFORM A COMPARATIVE ANALYSIS WITH NEWBORNS IN INTERNATIONAL
BETWEEN FEBRUARY AND JULY 2019 AND 2020, PERIOD OF THE SEASONALITY
OF APPLICATION OF PALIVIZUMABE, IN NEONATAL UNIT, USING THE
INDICATOR MODEL. THE DATA COLLECTION WAS PERFORMED THROUGH THE
PROTOCOL OF APPLICATION OF THIS MEDICATION. THE OBJECTIVE IS TO
PERFORM COMPARATIVE ANALYSIS IN ORDER TO IDENTIFY THE RELEVANCE
OF USING THE METHOD, REDUCING MATERIAL COSTS AND RESOURCES, AND A
SIGNIFICANT AND EFFECTIVE IMPROVEMENT IN THE ACTIONS DEVELOPED AS,
WHEN USED AND PERMITTING, IN THE USE OF THE PERMANENT RESOURCES OF
MANAGEMENT, TAKING THE FEEDBACKS OF THE MISCELLANEOUS
PROFESSIONALS INVOLVED, AS WELL AS THE CLIENT, WITH ASSERTIVE USE,
AVOIDING INCREASED INCREASE IN STAYS AND RETURN TO THE HOSPITAL. WE
CAN OBSERVE THAT THERE WAS A CONSIDERABLE COST REDUCTION AND A
SIGNIFICANT 65% SAVING ON THE FINAL VALUE OF THE PRODUCT FOR THE
COMPANY.
Keywords: balanced scorecard; cost-benefit; neonatal; palivizumabe.